Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration

Inclusion Criteria

• •1. Subjects BMI:
• •1. obese groups: subject must have a BMI ≥35 kg/m2 at the time of inclusion or has undergone bariatric surgery;
• •2. non-obese group: subject must have a BMI ≥18.5 and \<30 kg/m2 at the time of inclusion;
• •2. Subject is at least 18 of age on the day of screening and not older than 65 years of age on the day of dosing;
• •3. Subject able and willing to sign the Informed Consent before screening evaluations.
• •4. If a woman, is neither pregnant nor able to become pregnant and is not nursing an infant.
• •5. Subject is in good age-appropriate health condition as established by medical history, physical examination, electrocardiography, results of biochemistry and hematology within 6 weeks prior to study drug administration. Results of biochemistry and hematology should be within the laboratory's reference ranges (see Appendix A). If laboratory results are not within the reference ranges, the subject is included based on the investigator's judgment that the observed deviations are not clinically relevant. This should be clearly recorded.